Well differentiated thyroid carcinoma: Current treatment

J. Kenneth Byrd, Robert J. Yawn, Christina S.T. Wilhoit, Nicoleta D. Sora, Linda Meyers, Jyotika Fernandes, Terry Day

Research output: Contribution to journalArticle

10 Scopus citations


Opinion statement: Well differentiated thyroid carcinoma (WDTC) is a relatively common malignancy accounting for an estimated 37,000 thousand cases in the United States in 2009 [1]. WDTC also has a generally high 5 year survival rate that correlates with age. Papillary thyroid carcinoma (PTC) greater than 1 cm is best managed by total thyroidectomy. Thyroid lobectomy and isthmusectomy may be adequate for unifocal PTC less than 1 cm in patients without negative prognostic factors. Central compartment and possible lateral neck dissections should be performed when nodal metastases are present in the respective nodal basins. Post-operatively, radioactive iodine ablation with 131I followed by thyroid stimulating hormone (TSH) suppression is indicated in certain patients to improve locoregional control and reduce recurrence.

Original languageEnglish (US)
Pages (from-to)47-57
Number of pages11
JournalCurrent Treatment Options in Oncology
Issue number1
StatePublished - Mar 1 2012
Externally publishedYes


  • Papillary thyroid cancer
  • Thyroglobulin
  • Thyroid cancer
  • Thyroidectomy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Well differentiated thyroid carcinoma: Current treatment'. Together they form a unique fingerprint.

  • Cite this

    Byrd, J. K., Yawn, R. J., Wilhoit, C. S. T., Sora, N. D., Meyers, L., Fernandes, J., & Day, T. (2012). Well differentiated thyroid carcinoma: Current treatment. Current Treatment Options in Oncology, 13(1), 47-57. https://doi.org/10.1007/s11864-011-0173-1